Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, will concurrently present new data from ...
| Ticker |
Sentiment |
Impact |
|
ALLO
|
Somewhat Bullish
|
56 %
|
|
CLLS
|
Neutral
|
4 %
|
